WebObjectives: To compare the urinary pH, recurrence-free survival (RFS), and safety of adjuvant intravesical therapy in patients with non-muscle-invasive bladder cancer (NMIBC) receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy. Patients and methods: A total of 165 patients with NMIBC from six hospitals …
Chemotherapy for Bladder Cancer
WebJan 31, 2024 · Together, these findings indicate that BCG is a mainstay therapy commonly used in HR-NMIBC in real-world clinical practice settings, with the use of intravesical mitomycin C, chemotherapy, and surgery being more variable and less common. WebObjectives: To compare the urinary pH, recurrence-free survival (RFS), and safety of adjuvant intravesical therapy in patients with non-muscle-invasive bladder cancer … how to optifine download
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder …
WebFeb 25, 2015 · 1.3.3 Offer people with newly diagnosed intermediate‑risk non‑muscle‑invasive bladder cancer a course of at least 6 doses of intravesical mitomycin C. 1.3.4 If intermediate‑risk non‑muscle‑invasive bladder cancer recurs after a course of intravesical mitomycin C, refer the person's care to a specialist urology … WebSep 25, 2024 · Rigatti, P., Lev, A. & Colombo, R. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative … WebObjective: The aim of this work was to verify the tolerability and the preliminary clinical results of intensive intravesical instillations of a mitomycin C (MMC) regimen. Patients … how to optical cables work